Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
- Shanghai Fosun Pharmaceutical and AriBio signed an exclusive global option agreement for the development and commercialization of AR1001, a drug candidate for Alzheimer's disease treatment.
- Fosun Pharma will pay AriBio a US$60 million option fee and may exercise the option within the agreed period.
- AR1001 is a once-daily oral phosphodiesterase-5 inhibitor in a global Phase 3 clinical trial for early Alzheimer's disease and shows multiple therapeutic effects.
- The agreement expands their partnership to global markets including the US, Europe, and Japan, aiming to offer a new treatment option if the Phase 3 trials prove successful.
36 Articles
36 Articles
The Courier-Tribune
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease
SHANGHAI and SEONGNAM, South Korea, May 13, 2026 /PRNewswire/ -- On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced…
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease - PressReach
SHANGHAI and SEONGNAM, South Korea, May 13, 2026 /PRNewswire/ — On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. (“AriBio”), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced the signing of an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug…
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
